OnkoSight Myeloid Seq OnkoMyelo

Synonyms

Allscripts (AEHR) Order Name

OnkoSight Myeloid Seq.

Sunrise Clinical Manager (SCM) Order Name

OnkoSight Myeloid Disorder Panel

EPIC Order Name

OnkoSight Myeloid Seq

Clinical Info

Tumor sequencing by NGS detecting mutations in 50 genes associated with myeloid malignancies.
Mutations often have prognostic significance, may confer resistance to FDA approved
therapies, or may qualify patients for late-stage clinical trials.

Specimen Type

Blood, Bone Marrow

Container

Sterile

Collection Instructions

Peripheral Blood - Lavender Top or  Green Top Tube
Bone Marrow - Green Top
Eppendorf tube, Unstained Slide, Formalin-fixed, Paraffin-embedded Tissue
Decalcified specimens are not recommended for NGS testing
 **  Note: Please indicate specimen type on tube **
                 Test Code TL95

Transport Instructions

Room Temperature

Specimen Stability

7 Days Refrigerated Blood samples older than 7 days can still be shipped, they will be tested if the yield and quality of DNA permit.

Methodology

Genotyping by Next Generation Sequencing
Includes:
Genes ABL1; ANKRD26; ASXL1; ATRX; BCOR; BCORL1; BRAF
CALR; CBL; CCND2; CDKN2; CEBPA: CSF3R; CUX1
DDX41: DNMT3A: ETNK1: ETV6: EZH2: FBXW7; FLT3
GATA2; HRAS; IDH1; JAK2; KDM6A; KIT; KMT2A; KRAS
MAP2K1; MPL; MYD88; NF1; NPM1; NRAS; PDGFRA
PHF6; PTEN; PTPN11; RUNX1; SETBP1; SF3B1; SRSF2
STAG2; TET2; TP53; U2AF1; WT1; ZRSR2

Days Performed

TAT: 10 - 12 Days

Performing Laboratory

Genpath BioReference

CPT

81450
81451

PDM

1659893

Result Interpretation

See Report

 

Forms